Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
NCT ID: NCT06787482
Last Updated: 2025-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
100 participants
INTERVENTIONAL
2024-11-12
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Objectives:
Primary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure.
Secondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers.
Study Design:
Type: Open-label, single-arm interventional study. Duration: 12 months.
Participants: 150 adults, divided into three cohorts:
Retinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR).
Intervention:
A sublingual solution containing peptides and growth factors, taken 4 times daily.
Outcome Measures:
Primary Outcomes: Safety (adverse events) and tolerability (treatment adherence).
Secondary Outcomes:
Functional: Visual acuity and field sensitivity improvements. Structural: Retinal thickness and vascular health. Biomarkers: Serum VEGF, oxidative stress, and inflammatory markers.
Study Procedures:
Monthly follow-ups for safety monitoring, vision tests, retinal imaging (OCT, FA), and blood biomarker analysis.
Comprehensive evaluations at baseline, 6 months, and 12 months. Significance: The study aims to provide an innovative, non-invasive treatment for debilitating retinal conditions, potentially improving vision and retinal health through systemic therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684
Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
NCT02868424
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
NCT00299507
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
NCT00346957
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Authors :
Mohamed Yasser Sayed Saif Prof of ophthalmology , Beni-Suef University Sherin Amer Family medicine consultant, Alaa Abdelkarim Endocrinology consultant , ACE Cells Lab Ahmed Tamer Sayed Saif Assistant Professor of ophthalmology, Fayoum University Passant Sayed Saif Assistant Professor of Ophthalmology, Misr University for Science and Technology
1. Background and Rationale Retinal diseases such as retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR) are among the leading causes of blindness worldwide. These conditions result from different pathophysiological mechanisms but share common features like oxidative stress, chronic inflammation, and cellular degeneration.
The novel therapy under evaluation consists of low molecular weight peptides derived from fetal tissues and mesenchymal stem cells (MSCs). The formulation also incorporates bioactive growth factors and essential peptides to support retinal health and regeneration. Sublingual administration ensures systemic absorption and avoids invasive delivery methods.
2. Objectives
<!-- -->
1. Primary Objectives
* Assess the safety and tolerability of the peptide-based therapy.
* Evaluate its effects on retinal function and structure in patients with retinal dystrophies, AMD, and DR.
2. Secondary Objectives
* Explore improvements in visual function (acuity, field sensitivity).
* Monitor changes in retinal thickness and vascular health.
* Investigate its impact on disease biomarkers in the blood (e.g., VEGF, oxidative stress markers).
3. Study Design • Type: Open-label, interventional, single-arm study.
* Duration: 12 months.
* Participants: 150 participants, stratified equally into three cohorts:
* Cohort 1: Retinal dystrophies (e.g., macular dystrophy, Stargardt disease).
* Cohort 2: AMD (both dry and wet forms).
* Cohort 3: Diabetic retinopathy (moderate NPDR and PDR).
4. Participants 4.1 Inclusion Criteria
• Adults aged 18-80 years diagnosed with retinal dystrophies, AMD, or DR.
• BCVA between 20/40 and 20/400 in the study eye.
* Evidence of disease progression within the last 12 months (e.g., worsening visual acuity, OCT changes).
* Stable systemic conditions allowing safe participation. 4.2 Exclusion Criteria
* Active ocular infections or inflammation.
* Recent ocular surgeries (within 3 months).
* Co-existing advanced glaucoma or other retinal diseases.
* Pregnancy or breastfeeding.
* Hypersensitivity to components of the peptide formulation.
5. Intervention 5.1 Study Drug
• Formulation: Sublingual solution containing peptides derived from fetal retinal, optic nerve, and neural tissues, MSC-derived peptides, and platelet growth factors.
• Dosage: 1.0 mL sublingually, four times daily. 5.2 Administration
• Self-administered by participants in the morning and evening.
6. Outcome Measures 6.1 Primary Outcomes • Safety:
* Incidence and severity of adverse events (AEs) over 12 months. • Tolerability:
* Adherence to treatment regimen and participant-reported discomfort. 6.2 Secondary Outcomes
<!-- -->
1. Functional Outcomes:
o BCVA changes measured using ETDRS charts.
* Visual field sensitivity improvement assessed by automated perimetry.
2. Structural Outcomes:
o Retinal thickness and photoreceptor integrity evaluated by SD-OCT.
o Vascular leakage and neovascularization assessed using fluorescein angiography (FA) and OCT angiography (OCTA).
3. Biochemical and Biomarker Outcomes:
* Serum VEGF levels and oxidative stress markers.
* Inflammatory cytokine profiles (e.g., IL-6, TNF-α).
7\. Study Procedures 7.1 Screening Visit
1\. Informed Consent: Participants will provide written consent after a detailed explanation of the study.
2\. Baseline Assessments:
* Comprehensive medical and ocular history.
* BCVA measurement using ETDRS charts.
* SD-OCT imaging of retinal structure.
* FA and OCTA for vascular assessment.
* Blood sampling for biomarkers (VEGF, inflammatory cytokines). 7.2 Monthly Follow-Up Visits 1. Safety Monitoring: Documentation of AEs and systemic health assessment. 2. Ocular Assessments:
* BCVA measurement.
* SD-OCT imaging to monitor retinal thickness and integrity.
* OCTA and FA for vascular changes (if indicated). 7.3 Midpoint Visit (6 Months) 1. Repeat all baseline assessments, including biomarkers and electrophysiology (full-field ERG).
7.4 End-of-Study Visit (12 Months)
1. Comprehensive evaluation of functional, structural, and biochemical outcomes.
2. Participant feedback on therapy tolerability and perceived benefits.
8\. Statistical Analysis
1\. Sample Size Justification:
o Effect size and variability for BCVA improvement and retinal thickness changes are estimated from previous studies. A sample size of 150 ensures 80% power to detect a clinically meaningful difference at a 5% significance level.
2\. Data Analysis Plan:
* Continuous variables (e.g., BCVA, OCT metrics) analyzed using paired t-tests or ANOVA.
* Proportions of responders (e.g., those with BCVA improvement ≥5 letters) analyzed using chi-square tests.
* Correlation analysis between biomarkers and functional outcomes.
9\. Ethical Considerations
1. Regulatory Compliance:
* Conducted per the Declaration of Helsinki and ICH-GCP guidelines. 2. IRB Approval: Secured before study commencement. 3. Informed Consent: Participants provided detailed study information and signed consent forms.
4\. Data Confidentiality: All participant data anonymized and securely stored.
10\. References
1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection. Lancet Glob Health. 2014;2
. doi:10.1016/S2214-109X(13)70145-1.
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-36. doi:10.1016/S0140-6736(09)62124-3.
3. Scholl HP, Strauss RW, Singh MS, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8:368rv6. doi:10.1126/scitranslmed.aaf2838.
4. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-64. doi:10.2337/diacare.26.9.2653.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
administer 1 ml of Ace Retino 4 times daily for 6 months,safety evaluation
Primary Objective: Evaluate the safety and tolerability of ACE Retino in individuals with RP.
ACE Retino
1 ml sublingually self administer / 4 times/day for 6 months
test efficacy for ACE Retino 1 ml 4times daily sublingual for 6 months
Assess the efficacy of ACE Retino in improving retinal structure and function. Explore the potential for photoreceptor and retinal pigment epithelial (RPE) regeneration.
ACE Retino
1 ml sublingually self administer / 4 times/day for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACE Retino
1 ml sublingually self administer / 4 times/day for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Visual acuity of ≥1/60 in at least one eye.
* Stable ocular and systemic condition over the past six months.
* Ability to provide written informed consent
Exclusion Criteria
* Recent ocular surgery (within six months) or current use of investigational drugs.
* Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases).
* Pregnancy or lactation.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Wellness Academy
INDUSTRY
Ace Cells Lab Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Passant Sayed Saif, PhD ophthalmology
Role: PRINCIPAL_INVESTIGATOR
Associate prof of Ophthalmology Misr University for science and technology
Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology
Role: PRINCIPAL_INVESTIGATOR
Dean of NILES Prof of Ophthalmology Beni-Suef University
Dr. Alaa Abdelkarim Mohammed, MRCPUK Endocirnology
Role: PRINCIPAL_INVESTIGATOR
ACE Cells Lab Limited Chief Medical Consultant
Dr. Ahmed Tamer Sayed Saif, PhD Ophthalmology
Role: PRINCIPAL_INVESTIGATOR
Chairman of Ophthalmology department Associate prof of Ophthalmology Fayoum university
DR. Mike Chan, stem cells expert
Role: STUDY_CHAIR
European Wellness Academy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Seif Clinic
Cairo, , Egypt
British Center for Regeerative medicne (Cairo)
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr. Mohammed Yasser Sayed Saif, PhD Ophthalmology, professor
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACE_Retino_EG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.